Why the study?
The relationship between serum adiponectin concentration and type 2 diabetes has been conflicting, possibly due to the extent of kidney damage present.
Is the ratio of serum adiponectin to urinary albumin/creatinine ratio a better marker for type 2 diabetes than serum adiponectin alone?
Is the ratio of serum adiponectin to urinary albumin/creatinine ratio a better marker for type 2 diabetes than serum adiponectin alone?
The relationship between serum adiponectin and type 2 diabetes is better evaluated when accounting for the extent of kidney damage (uACR).
Answers are grounded in this paper and cite their sources.
May clarify conflicting adiponectin-T2D reports after kidney adjustment; leaves open causal inference pending longitudinal data.
The relationship between serum adiponectin concentration (S-Adipo) and various diseases, such as type 2 diabetes (T2D) is conflicting. We hypothesized that the extent of kidney damage in patients with T2D may be responsible for this inconsistency and, thus, examined association between S-Adipo and T2D after consideration for the extent of kidney damage present. Of the 1816 participants in the population-based Iwaki study of Japanese people, 1751 participants with a complete dataset were included. Multivariate logistic regression analyses revealed that low S-Adipo was independently associated with T2D (<0.001), as was high urinary albumin to creatinine ratio (uACR) (<0.001). Principal components analysis showed that the relative value of S-Adipo to uACR (adiponectin relative excess) was significantly associated with T2D (odds ratio: 0.49, p < 0.001). Receiver operating curve analyses revealed that an index of adiponectin relative excess the ratio of S-Adipo to uACR was superior to S-Adipo per se as a marker of T2D (area under the curve: 0.746 vs. 0.579, p < 0.001). This finding indicates that the relationship between S-Adipo and T2D should be evaluated according to the extent of kidney damage present and may warrant similar analyses of the relationships between S-Adipo and other medicalconditions, such as cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Ono et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: